You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 9 Next »

  • Date

  

Attendees  

Attendees  

Goals

  • PGx and Oncology Cross-team Meeting to discuss outstanding PGx change requests and additional items

Discussion items  

TimeItemWhoNotes
1.5hr

PGx Change Requests - Characterization of the Tumor: Primary, Metastatic, etc. (BSTEST row 11)　

Erin/Joyce
 PGx Change Requests - including MRD Minimal Residual Disease (PF row 7)  
Examples for PGx Use Cases Template-2017-01-16 Consolidated-Team.xlsx

 

  • See PGx P30 working document -

    • PFTEST row 7 - minimal residual disease - Do not add as new PFTEST. Keep in RS. Use REFID to link PF data to RS.

    • PFTEST row 13, 14 - These tests would be used with the MRD terminology in RS. Team agrees to add Clone Frequency. Team to discuss 'Myeloma cells/Leukocytes' on next call.

Team agreed one more call was required on . Next Call items to discuss: BSTEST Row 11; PFTEST row 13, 14

Discussion items  

TimeItemWhoNotes
45min

Characterization of the Tumor: Primary, Metastatic, etc. (BSTEST row 11)

Erin/Joyce/Melanie

BSTEST Row 11

45min MRD - PFTEST row 13, 14　Erin/Joyce/Melanie 

PFTEST row 13, 14

 

 

Action items

  • Erin Muhlbradt to send NCCN and Bruggerman MRD papers to PGx team

  • Erin Muhlbradt to draft TEST name and definition for new BSTEST term on row 11 and PFTEST row 13, 14.
  • Melanie Paules to send out PGx invite to Oncology team for next meeting on 2017-02-27
  •  

 

 

  • No labels